Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

• Published in: Clinical cancer research Vol. 14; no. 12; pp. 3906 - 3915
• Main Authors: VERSTOVSEK, Srdan, TEFFERI, Ayalew, KANTARJIAN, Hagop, CORTES, Jorge, O'BRIEN, Susan, GARCIA-MANERO, Guillermo, PARDANANI, Animesh, AKIN, Cem, FADERL, Stefan, MANSHOURI, Taghi, THOMAS, Deborah
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.06.2008
• Subjects: acute myeloid leukemia; Adult; Aged; Antineoplastic agents; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Dasatinib; Female; Humans; hypereosinophilic syndrome; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myeloid, Acute - drug therapy; Male; Mastocytosis, Systemic - drug therapy; Medical sciences; Middle Aged; myelodysplastic syndrome; Pharmacology. Drug treatments; Philadelphia Chromosome; primary myelofibrosis; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Remission Induction; systemic mastocytosis; Thiazoles - adverse effects; Thiazoles - therapeutic use; Treatment Outcome; Chromosomal aberration; Antineoplastic agent; Human; Dasatinib; Mastocytosis; Tyrosine kinase inhibitor; Chronic disease; Acute; Philadelphia chromosome; Abnormal chromosome C9; Treatment; Phase II trial; Systemic disease; Abnormal chromosome G22; Abnormal chromosome; Multikinase inhibitor

Purpose: Molecular characterization of Philadelphia chromosome–negative (Ph−) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent agai...